Statistical analysis
All statistical analyses were conducted using SAS version 9.4 (or higher). The safety and efficacy were assessed in those patients who received at least 1 dose of pemigatinib. The PK characteristics were established from the PK analysis set (patients who had received at least one dose of pemigatinib and provided at least one post-baseline PK samples as per protocol).Standard non-compartmental pharmacokinetic methods with PKanalix2020R1 (Lixoft, Antony, France) were applied to estimate PK parameters, including AUC, CThe Clopper-Pearson method was used to calculate the 95% confidence interval (CI) of ORR and DCR. The Kaplan–Meier method and the Brookmeyer and Crowley method were used to estimate PFS.